Pharma Conversation & Community - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharma Conversation & Community
A round up of news from across the web, including trends from social social media platforms.

Pharmaceutical Technology
Volume 37, Issue 1


FDA Issues Draft Guidance on Electronic Submissions

FDA has issued a draft guidance, Guidance for Industry: Providing Submissions in Electronic Format—Summary Level Clinical Site Data for CDER's Inspection Planning, which is one in a series of documents intended to assist sponsors and applicants making certain regulatory submissions to FDA in electronic format.

US Supreme Court to Hear Pay-for-Delay Case

The US Supreme Court agreed to hear a case that will decide whether brand-name drug companies may pay generic drug-companies to delay introduction of lower-cost generic drugs. The Supreme Court is to review a federal appeals court ruling that upheld a "pay-for-delay" arrangement.

Ranbaxy Recalls Atorvastatin Due to Quality Issues

Ranbaxy Pharmaceuticals is recalling certain lots of its atorvastatin tablets because of possible contamination with small glass particles (less than 1 mm in size). Ranbaxy has ceased atorvastatin manufacturing until it has thoroughly investigated the problem.


  • Valeant Pharmaceuticals International has completed its acquisition of Medicis Pharmaceutical.
  • Isochem has expanded its range of intermediates by acquiring the British fine-chemicals company, Wychem.
  • French contract manufacturing firm Synerlab has acquired lyophilization specialist company Lyofal.
  • Amgen has agreed to buy Icelandic-based Decode Genetics for $415 million in an all-cash transaction.


PharmTech is seeking reader input for a future feature on parenteral drug manufacturing. Send your questions and thoughts to the Community Manager, Stephanie Sutton, at

Take part in our latest poll at:


"Real-time devices for continuous feeding processes were discussed at a seminar I recently attended."

Jennifer Markarian,

See more posts at


  • Pharma companies using new analytical methods to ensure quality of medicine
  • How to optimize continuous processing and make it work in pharmaceutical manufacturing is a crucial issue.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here